Santen Pharmaceutical Co (SNPHF) Price & Analysis

Compare

6 Followers

SNPHF Stock Chart & Stats

$10.60

$0.00(0.00%)

At close: Dec 09 4:00 PM EST

$10.60

$0.00(0.00%)

Day’s Range― - ―

52-Week Range$8.11 - $12.54

Previous CloseN/A

Volume1.00K

Average Volume (3M)0.00

Market Cap

$3.35B

Enterprise Value$513.05B

Total Cash (Recent Filing)$66.08B

Total Debt (Recent Filing)$35.63B

Price to Earnings (P/E)16.9

Beta-0.09

Next Earnings

Feb 05, 2026

EPS Estimate

0.18

Next Dividend Ex-DateN/A

Dividend Yield2.47%

Share Statistics

EPS (TTM)0.16

Shares Outstanding322,268,550

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.32

Price to Book (P/B)1.73

Price to Sales (P/S)1.65

P/FCF Ratio9.11

Enterprise Value/Market Cap152.95

Enterprise Value/Revenue1.76

Enterprise Value/Gross Profit3.19

Enterprise Value/Ebitda8.30

Forecast

1Y Price Target

$14.13

Price Target Upside33.29% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Santen Pharmaceutical Co News

Santen Pharmaceutical Reports Decline in Financial Performance but Maintains Dividend Strategy

Santen Pharmaceutical Co ( ($JP:4536) ) has shared an update. Santen Pharmaceutical Co. reported a decline in its...

2M ago

Santen Pharmaceutical to Cancel 19.8 Million Treasury Shares

Santen Pharmaceutical Co ( ($JP:4536) ) has shared an update. Santen Pharmaceutical Co., Ltd. announced the cancellation of...

2M ago

Santen Completes Share Buyback to Enhance Shareholder Value

An announcement from Santen Pharmaceutical Co ( ($JP:4536) ) is now available. Santen Pharmaceutical Co. announced the completion...

2M ago

Santen Pharmaceutical Updates on Share Buyback Progress

An update from Santen Pharmaceutical Co ( ($JP:4536) ) is now available. Santen Pharmaceutical Co., Ltd. announced the...

2M ago

Santen Completes Disposal of Treasury Shares for Stock Remuneration Plan

An announcement from Santen Pharmaceutical Co ( ($JP:4536) ) is now available. Santen Pharmaceutical Co., Ltd. has completed...

2M ago

Santen Pharmaceutical Announces Disposal of Treasury Shares for Stock Remuneration Plan

Santen Pharmaceutical Co ( ($JP:4536) ) has issued an announcement. Santen Pharmaceutical Co., Ltd. has announced the disposal...

3M ago

Santen Pharmaceutical Reports Progress on Share Buyback Initiative

Santen Pharmaceutical Co ( ($JP:4536) ) has shared an announcement. Santen Pharmaceutical Co., Ltd. announced the status of...

3M ago

Santen Pharmaceutical Suspends Treasury Share Disposal Plan

The latest update is out from Santen Pharmaceutical Co ( ($JP:4536) ). Santen Pharmaceutical Co. has announced the...

3M ago

Santen Pharmaceutical Announces Treasury Share Disposal for Performance-linked Remuneration

Santen Pharmaceutical Co ( ($JP:4536) ) has issued an update. Santen Pharmaceutical Co., Ltd. has announced the disposal...

4M ago

Santen Pharmaceutical Updates on Share Buyback Progress

Santen Pharmaceutical Co ( ($JP:4536) ) just unveiled an update. Santen Pharmaceutical Co., Ltd. announced the status of...

4M ago

Clearside Biomedical’s partner signed new collaboration agreement with Santen

Clearside Biomedical (CLSD) announced today that the Company’s Asia-Pacific partner, Arctic Vision, has signed a new commercial collaboration...

1y ago

CLSD

Ocular Therapeutix appoints Graves to board of directors

Ocular Therapeutix (OCUL) announced the appointment of Adrienne Graves, Ph.D., to its Board of Directors. As the former...

2y ago

OCUL

SNPHF FAQ

What was Santen Pharmaceutical Co Ltd’s price range in the past 12 months?

Santen Pharmaceutical Co Ltd lowest stock price was $8.11 and its highest was $12.54 in the past 12 months.

What is Santen Pharmaceutical Co Ltd’s market cap?

Santen Pharmaceutical Co Ltd’s market cap is $3.35B.

When is Santen Pharmaceutical Co Ltd’s upcoming earnings report date?

Santen Pharmaceutical Co Ltd’s upcoming earnings report date is Feb 05, 2026 which is in 41 days.

How were Santen Pharmaceutical Co Ltd’s earnings last quarter?

Santen Pharmaceutical Co Ltd released its earnings results on Nov 06, 2025. The company reported $0.156 earnings per share for the quarter, beating the consensus estimate of $0.133 by $0.023.

Is Santen Pharmaceutical Co Ltd overvalued?

According to Wall Street analysts Santen Pharmaceutical Co Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Santen Pharmaceutical Co Ltd pay dividends?

Santen Pharmaceutical Co Ltd pays a Semiannually dividend of $0.123 which represents an annual dividend yield of 2.47%. See more information on Santen Pharmaceutical Co Ltd dividends here

What is Santen Pharmaceutical Co Ltd’s EPS estimate?

Santen Pharmaceutical Co Ltd’s EPS estimate is 0.18.

How many shares outstanding does Santen Pharmaceutical Co Ltd have?

Santen Pharmaceutical Co Ltd has 322,268,550 shares outstanding.

What happened to Santen Pharmaceutical Co Ltd’s price movement after its last earnings report?

Santen Pharmaceutical Co Ltd reported an EPS of $0.156 in its last earnings report, beating expectations of $0.133. Following the earnings report the stock price went down -1.314%.

Which hedge fund is a major shareholder of Santen Pharmaceutical Co Ltd?

Currently, no hedge funds are holding shares in SNPHF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Santen Pharmaceutical Co Ltd

Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.

Santen Pharmaceutical Co (SNPHF) Earnings & Revenues

Historic Earnings Reports

SNPHF Stock 12 Month Forecast

Average Price Target

$14.13

▲(33.29% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","15":"$15","9.75":"$9.75","11.5":"$11.5","13.25":"$13.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14.1284,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$14.13</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.1284,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$14.13</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.1284,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.13</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,9.75,11.5,13.25,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2021","6":"Aug<br/>2024","9":"Jun<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.51,9.865261538461539,10.220523076923076,10.575784615384615,10.931046153846154,11.286307692307691,11.64156923076923,11.996830769230769,12.352092307692306,12.707353846153845,13.062615384615384,13.417876923076921,13.77313846153846,{"y":14.1284,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.51,9.865261538461539,10.220523076923076,10.575784615384615,10.931046153846154,11.286307692307691,11.64156923076923,11.996830769230769,12.352092307692306,12.707353846153845,13.062615384615384,13.417876923076921,13.77313846153846,{"y":14.1284,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.51,9.865261538461539,10.220523076923076,10.575784615384615,10.931046153846154,11.286307692307691,11.64156923076923,11.996830769230769,12.352092307692306,12.707353846153845,13.062615384615384,13.417876923076921,13.77313846153846,{"y":14.1284,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.09,"date":1614556800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":12.09,"date":1617235200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":12.09,"date":1617235200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":12.09,"date":1625097600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":12.09,"date":1627776000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":9.91,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.24,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.9,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.43,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.88,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.32,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.45,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.51,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >